(TERMINATED 06.07.10) Prot# CNTO1275PSA3001: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Psoriatic Arthr

Project: Research project

Project Details

StatusFinished
Effective start/end date1/20/106/7/10

Funding

  • Janssen Research & Development, LLC (CNTO1275PSA3001 // CNTO1275PSA3001)
  • Centocor, Inc (CNTO1275PSA3001 // CNTO1275PSA3001)